NVCR NovoCure Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVCR

Price (delayed)

$15.59

Market cap

$1.66B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.64

Enterprise value

$2.09B

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating ...

Highlights
The net income has plunged by 156% YoY and by 24% from the previous quarter
NVCR's EPS has dropped by 152% year-on-year and by 23% since the previous quarter
Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: http://www.novocure.com
Peers: ONVO ORTX

Key stats

What are the main financial stats of NVCR
Market
Shares outstanding
106.62M
Market cap
$1.66B
Enterprise value
$2.09B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.98
Price to sales (P/S)
3.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.12
Earnings
Revenue
$507.66M
EBIT
-$190.5M
EBITDA
-$179.7M
Free cash flow
-$45.9M
Per share
EPS
-$1.64
Free cash flow per share
-$0.43
Book value per share
$3.91
Revenue per share
$4.78
TBVPS
$10.9
Balance sheet
Total assets
$1.16B
Total liabilities
$743.33M
Debt
$587.48M
Equity
$415.68M
Working capital
$915.4M
Liquidity
Debt to equity
1.41
Current ratio
7.1
Quick ratio
6.88
Net debt/EBITDA
-2.39
Margins
EBITDA margin
-35.4%
Gross margin
75.9%
Net margin
-34.3%
Operating margin
-37.5%
Efficiency
Return on assets
-14.8%
Return on equity
-40.2%
Return on invested capital
-13.3%
Return on capital employed
-18.9%
Return on sales
-37.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
-3.47%
1 week
-10.09%
1 month
-30.06%
1 year
-79.48%
YTD
-78.75%
QTD
-3.47%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$507.66M
Gross profit
$385.39M
Operating income
-$190.5M
Net income
-$174.36M
Gross margin
75.9%
Net margin
-34.3%
NovoCure's net margin has plunged by 174% YoY and by 27% from the previous quarter
The net income has plunged by 156% YoY and by 24% from the previous quarter
NovoCure's operating margin has decreased by 32% QoQ
NovoCure's operating income has decreased by 28% QoQ

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
NVCR P/E details
P/E
N/A
P/B
3.98
P/S
3.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.12
NVCR's EPS has dropped by 152% year-on-year and by 23% since the previous quarter
The price to book (P/B) is 86% lower than the 5-year quarterly average of 28.5 and 73% lower than the last 4 quarters average of 15.2
The equity has declined by 6% year-on-year and by 3.8% since the previous quarter
NVCR's price to sales (P/S) is 83% lower than its 5-year quarterly average of 19.6 and 73% lower than its last 4 quarters average of 12.5
The company's revenue fell by 7% YoY and by 2.8% QoQ

Efficiency

How efficient is NovoCure business performance
NovoCure's return on equity has shrunk by 151% YoY and by 26% QoQ
The company's return on assets has shrunk by 147% YoY and by 23% QoQ
NVCR's return on sales is down by 32% since the previous quarter
NovoCure's ROIC has decreased by 23% from the previous quarter

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total assets is 56% more than its total liabilities
The company's quick ratio fell by 13% YoY and by 3.2% QoQ
The company's current ratio fell by 12% YoY and by 3% QoQ
NovoCure's debt is 41% more than its equity
NVCR's debt to equity is up by 8% YoY and by 3.7% QoQ
The equity has declined by 6% year-on-year and by 3.8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.